New England Surgical Society (NESS)
Search NESS
  Home
  Annual Meeting
  Annual Resident and Fellow Research Day
  Members
      Member Directory
      Members Only
  Scholars Foundation
  Job Board
  Awards
  Journal of the American College of Surgeons
  Newsletters
  Committees
  Contact NESS

2010 Annual Meeting Abstracts

Back to Program


Oral Pterostilbene Inhibits Pancreatic Cancer Growth in a Mouse Model
*Patrick Mannal, David McFadden
University of Vermont, Burlington, VT

Objective: The current study is designed to evaluate the ability of orally administered Pterostilbene to inhibit pancreatic cancer tumor growth in vivo.
Design: Pilot study, animal xenograft model.
Setting: Animal care facility; tertiary care center with surgical oncology specialists.
Participants: 40 Nu/Nu (athymic) mice.
Interventions: Pancreatic cancer cells (MIA PaCa-2) were cultured using standard techniques. 40 Nu/Nu (athymic) mice were inoculated with 6 x 106 MIA pancreatic cancer cells in the right flank. Once the tumor volumes reached 150mm³, oral Pterostilbene in its vehicle DMSO was administered in concentrations of 100µg/kg/day, 500µg/kg/day, or 1mg/kg/day for 8 weeks. DMSO plus water was used as a control. Tumor volumes and animal weights were recorded three times weekly.
Main Outcome Measures: Rate of tumor growth in treatment vs. control groups after initiation of oral Pterostilbene administration.
Results: Using an exponential tumor growth model, unique tumor growth rate parameters for each of the 4 animal groups were formulated. Growth rate parameters were as follows: Control (0.0522), 100µg/kg/day (0.0260), 500µg/kg/day (0.0264), and 1mg/kg/day (0.0371). Based upon 95% confidence intervals, the 100µg/kg/day and 500µg/kg/day groups had statistically significant tumor growth inhibition versus controls. 100% of animals in the treatment arms survived, whereas the control group had a 66% survival rate. Histologically the tumors were similar across treatment groups, showing areas of central necrosis and perineural invasion typical of pancreatic adenocarcinoma.
Conclusions: This pilot study is the first to demonstrate oral Pterostilbene’s in vivo effectiveness against pancreatic cancer. While confirming our previous in vitro findings of Pterostilbene’s anti-cancer capabilities, these results justify larger in vivo studies and human trials to clarify effective dosing and treatment duration for this novel anti-cancer compound.


Back to Program

 

Copyright © 2018 New England Surgical Society. All Rights Reserved.
Read Privacy Policy.